The Future of Targeted Therapies for Acute Myeloid Leukemia
This activity is designed to address the unprecedented recent and ongoing advances in AML research and anticipated changes in the AML therapeutic landscape resulting from the development of many innovative therapies, several of which are in late stages of clinical trials. The goal of this activity is to ensure that members of a multidisciplinary team, including physicians, nurses, pharmacists and other relevant healthcare professionals, have the knowledge and skills necessary to apply the standards of care to their practice and healthcare setting for patients with AML.
This educational program is designed to meet the educational needs of oncologists, hematologists, nurses, pharmacists, and other healthcare professionals who manage patients with AML.
Upon completion of this educational activity, participants will be able to:
- Evaluate the prognostic implications and treatment needs of patients with acute myeloid leukemia (AML) characterized by poor-risk cytogenetic and molecular features
- Summarize the targets, mechanisms of action, and key efficacy/safety data for investigational targeted therapies for patients with AML
- Assess the evolving interprofessional roles of healthcare professionals in hematology/oncology in the context of anticipated changes in the AML therapeutic landscape
Jessica K. Altman, MD
Associate Professor of Medicine
Division of Hematology/Oncology
Northwestern University Feinberg School of Medicine
Director, Acute Leukemia Program
Robert H Lurie Cancer Center of Northwestern University
Richard M. Stone, MD
Professor of Medicine
Harvard Medical School
Chief of Staff and Director
Adult Acute Leukemia Program
Dana-Farber Cancer Institute
Disclosure of Relevant Financial Relationships
All faculty and activity planners participating in NCCN continuing education activities are expected to disclose any relevant financial relationships with a commercial interest as defined by the ACCME’s, ANCC’s, and ACPE’s Standards for Commercial Support. All faculty presentations have been reviewed for adherence to the ACCME’s Criterion 7: The provider develops activities/educational interventions independent of commercial interests (SCS 1, 2, and 6) by experts on the topics. Full disclosure of faculty relationships will be made prior to the activity.
The faculty listed below have disclosed the following relevant financial relationships:
Jessica K. Altman, MD: Astellas Pharma US, Inc.: Scientific Advisor; Bristol-Myers Squibb Company: Scientific Advisor; Fujifilm Corporation: Scientific Advisor; Janssen Pharmaceutica Products, LP: Scientific Advisor; Syros Pharmaceuticals: Scientific Advisor.
Richard M. Stone, MD: Agios Pharmaceuticals, Inc.: Consulting Fees, Honoraria; Amgen, Inc.: Consulting Fees, Honoraria; Arog Pharmaceuticals, Inc.: Consulting Fees, Honoraria; Bristol-Myers Squibb Company: Consulting Fees, Honoraria; Celator Pharmaceuticals, Inc.: Consulting Fees, Honoraria; Celgene Corporation: Consulting Fees, Honoraria; Fujifilm Corporation: Consulting Fees, Honoraria; Janssen Pharmaceutica Products, LP: Consulting Fees, Honoraria; Karyopharm Therapeutics: Consulting Fees, Honoraria; Merck & Co., Inc.: Consulting Fees, Honoraria; Novartis Pharmaceuticals Corporation: Consulting Fees, Honoraria; Onyx Pharmaceuticals, Inc.: Consulting Fees, Honoraria; Pfizer, Inc.: Consulting Fees, Honoraria.
The activity planning staff listed below has no relevant financial relationships to disclose:
NCCN: Mark Geisler; Kristina M. Gregory, RN, MSN, OCN; Kristin Kline Hasson; Rose Joyce; Karen Kanefield; Joan S. McClure, MS; Diane McPherson; Melanie Moletzsky; Deborah Moonan, RN, BSN; Lisa Perfidio; Liz Rieder; Shannon K. Ryan; Kathy Smith; Jennifer McCann Weckesser
PRIME: Keith Whitener
The clinical information team listed below, who have reviewed content, has the following relevant financial relationships to disclose:
Courtney Smith, PhD: Johnson & Johnson: Equity Interest/Stock Options; Opko Health, Inc: Equity Interest/Stock Options
Tamar Sapir, PhD: Salary/Contractual
Cherilyn Heggen-Peay, PhD: Salary/Contractual
The ACCME/ANCC/ACPE defines “conflict of interest” as when an individual has an opportunity to affect CE content about products or services of a commercial interest with which he/she has a financial relationship.
ACCME, ACPE, and ANCC focuses on financial relationships with commercial interests in the 12-month period preceding the time that the individual is being asked to assume a role controlling content of the CE activity. ACCME, ACPE, and ANCC have not set a minimal dollar amount for relationships to be significant. Inherent in any amount is the incentive to maintain or increase the value of the relationship. The ACCME, ACPE, and ANCC defines “’relevant’ financial relationships” as financial relationships in any amount occurring within the past 12 months that create a conflict of interest.
All faculty for this continuing education activity are competent in the subject matter and qualified by experience, training, and/or preparation to the tasks and methods of delivery.
National Comprehensive Cancer Network (NCCN) is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
National Comprehensive Cancer Network designates this enduring activity for a maximum of 0.75 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
AAPA accepts certificates of participation for educational activities certified for AMA PRA Category 1 Credit™ from organizations accredited by ACCME or a recognized state medical society. Physician assistants may receive a maximum of 0.75 hours of Category I credit for completing this program.
National Comprehensive Cancer Network (NCCN) is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s (ANCC) Commission on Accreditation. NCCN designates this educational activity for a maximum of 0.79 contact hours. Accreditation as a provider refers to the recognition of educational activities only; accredited status does not imply endorsement by NCCN or ANCC of any commercial products discussed/displayed in conjunction with the educational activity.
Kristina M. Gregory, RN, MSN, OCN, is our lead nurse planner for this educational activity.
|National Comprehensive Cancer Network is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.|
Type of Activity: Knowledge
National Comprehensive Cancer Network designates this continuing education activity for 0.75 contact hour (0.075 CEUs) of continuing education credit in states that recognize ACPE accredited providers (Universal Activity Number 0836-9999-16-108-H01-P).
- 0.75 ACPE contact hours
- 0.79 ANCC contact hours
- 0.75 AMA PRA Category 1 Credit™
- 0.75 Participation